



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FIL	LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/476,202	09/476,202 01/03/2000		JOHN D. NOTI	052544-0108	7459
23524	7590	07/14/2004			XAMINER
FOLEY &			KATCHEVES, KONSTANTINA T		
150 EAST C P.O. BOX 1		TREET	ART UNIT	PAPER NUMBER	
MADISON, WI 53701-1497				1636	
				DATE MAILED: 07/14/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)					
	09/476,202	NOTI, JOHN D.					
Office Action Summary	Examiner	Art Unit					
	Konstantina Katcheves	1636					
The MAILING DATE of this communica Period for Reply	tion appears on the cover sheet with	n the correspondence address					
A SHORTENED STATUTORY PERIOD FOR THE MAILING DATE OF THIS COMMUNICA - Extensions of time may be available under the provisions of 3 after SIX (6) MONTHS from the mailing date of this communic If the period for reply specified above is less than thirty (30) dated in the provision of the provisi	ATION. 7 CFR 1.136(a). In no event, however, may a replation. ays, a reply within the statutory minimum of thirty by period will apply and will expire SIX (6) MONTI by statute, cause the application to become ABA	oly be timely filed (30) days will be considered timely. HS from the mailing date of this communication. NDONED (35 U.S.C. § 133).					
Status							
1) Responsive to communication(s) filed of	on <u>24 June 2003 and 04 March 200</u>	<u>03</u> .					
2a)⊠ This action is FINAL . 2b)	This action is FINAL . 2b) ☐ This action is non-final.						
	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims							
4) ☐ Claim(s) 1-43 is/are pending in the app 4a) Of the above claim(s) 18-43 is/are v 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 1,3-7,11-13,15 and 17 is/are r 7) ☐ Claim(s) 2,8-10,14 and 16 is/are object 8) ☐ Claim(s) are subject to restriction	vithdrawn from consideration. ejected. ed to.						
Application Papers							
9) The specification is objected to by the E							
10) The drawing(s) filed on 24 June 2003 is.		•					
Applicant may not request that any objectio Replacement drawing sheet(s) including the	- · · · · · · · · · · · · · · · · · · ·						
11) The oath or declaration is objected to by	,	, , ,					
Priority under 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for a) All b) Some * c) None of: 1. Certified copies of the priority doc 2. Certified copies of the priority doc 3. Copies of the certified copies of the application from the International * See the attached detailed Office action for	cuments have been received. cuments have been received in Ap he priority documents have been re Bureau (PCT Rule 17.2(a)).	plication No eceived in this National Stage					
	·						
Attachment(s)							
1) Notice of References Cited (PTO-892)	4) 🔲 Interview Su						
 Notice of Draftsperson's Patent Drawing Review (PTO-3) Information Disclosure Statement(s) (PTO-1449 or PTO Paper No(s)/Mail Date 		Mail Date ormal Patent Application (PTO-152) 					

Application/Control Number: 09/476,202

Art Unit: 1636

DETAILED ACTION

Claims 1-43 are pending. Claims 18-43 are withdrawn from consideration. Claims 1-17 are under consideration.

Election/Restrictions

The restriction requirement was made final in the prior Office action mailed 03 December 2002. According to 37 CFR 1.144, Applicant may petition the restriction requirement made final in the prior Office action on the merits:

After a final requirement for restriction, the applicant, in addition to making any reply due on the remainder of the action, may petition the Commissioner to review the requirement. Petition may be deferred until after final action on or allowance of claims to the invention elected, but must be filed not later than appeal. A petition will not be considered if reconsideration of the requirement was not requested (see § 1.181).

Response to Amendment

Claims 1, 3-7, 11-13, 15 and 17 stand rejected under 35 U.S.C. 112, first paragraph.

The rejection of the claims under 35 U.S.C. 112, second paragraph have been withdrawn in view of Applicant's amendments.

Response to Arguments

Claims 1, 3-7, 11-13, 15 and 17 stand rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor, at the time the application was filed, had possession of the claimed invention.

Application/Control Number: 09/476,202

Art Unit: 1636

Applicant argues that the written description requirement has been met because:

Example 1 describes the identification of the promoter, example 2 describes the isolation and sequence analysis of 'the 5' flanking region, example 3 describes the determination of the transcription CD1ld start site of the CD1ld gene, example 4 describes the functional analysis of the CD1ld promoter including the identification of several sequences that include the sequence that provides the promoter activity, example 5 describes the interaction of DNA binding proteins with the CD1ld sequence, example 6 describes sequence deletions that reduce activity of the promoter, example 7 regulation of the CD1ld promoter region, and example 8 describes myeloid-specific down regulation of CD1ld by PMA.

Although Applicant's disclosure teaches the elucidation of the promoter and in particular sequences in the promoter related to activity, it fails to provide written description for the broad genus claimed. The instant claims are drawn to sequences all or a functional portion of a promoter which includes one or more modifications such that the ability to direct myeloid cell specific expression is maintained, which may further comprise various modifications. It remains unclear what the functional portions and what modification can be made such that myeloid specific promoter activity can be maintained. The modifications recited in the claim embrace modifications anywhere within the promoter region including inside the cis-acting elements such that it is unknown what sequences embraced by the claim will result in functional activity. Moreover, the sequences embraced by broad language such as the language in claim 1 read on any fragments or portions of the CD11d gene promoter which represents a wide array of molecules. Therefore, the invention is not described in such full, clear and concise language as to indicate that Applicant was in possession of the invention.

Application/Control Number: 09/476,202

Art Unit: 1636

Allowable Subject Matter

Claims 2, 8-10, 14 and 16 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Konstantina Katcheves whose telephone number is (571) 272-0768. The examiner can normally be reached on Monday, Tuesday, Thursday and Friday 7:30 to 5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Remy Yucel, Ph.D. can be reached on (571) 272-0781. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Konstantina Katcheves Examiner Art Unit 1636

JAMES KETTER
PRIMARY EXAMINER